Editor’s note: A recording of the event is embedded below
Last summer Intellia reported the first data showing that CRISPR could be used in the body to combat a disease — in this case, a rare nerve disorder. That early data was so eye-catching it was published in the New England Journal of Medicine. But what are the next steps? The company’s CEO joins STAT to lay them out and answer your questions.
Featured Speakers:
- John Leonard, M.D., president and chief executive officer, Intellia Therapeutics
- Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
- Chris Coburn, chief innovation officer, Mass General Brigham (sponsor speaker)
- Christine “Kricket” Seidman, M.D., Brigham and Women’s Hospital (sponsor speaker)
- Larry Di Rita, Head of Public Policy, Bank of America (sponsor speaker)
About the Author Reprints
Create a display name to comment
This name will appear with your comment
